BRPI1013177A2 - construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca - Google Patents

construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca

Info

Publication number
BRPI1013177A2
BRPI1013177A2 BRPI1013177A BRPI1013177A BRPI1013177A2 BR PI1013177 A2 BRPI1013177 A2 BR PI1013177A2 BR PI1013177 A BRPI1013177 A BR PI1013177A BR PI1013177 A BRPI1013177 A BR PI1013177A BR PI1013177 A2 BRPI1013177 A2 BR PI1013177A2
Authority
BR
Brazil
Prior art keywords
antigen binding
heart disease
isolated polypeptide
binding construct
treating heart
Prior art date
Application number
BRPI1013177A
Other languages
English (en)
Inventor
Carolyn Enever
Edward Coulstock
Elena De Angelis
Jay Edelberg
Lahra Jawad-Alami
Stevie Holmes
Thil Dinuk Batuwangala
Victoria Ballard
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI1013177A2 publication Critical patent/BRPI1013177A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1013177A 2009-05-28 2010-05-26 construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca BRPI1013177A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18181409P 2009-05-28 2009-05-28
PCT/EP2010/057283 WO2010136508A2 (en) 2009-05-28 2010-05-26 Stem cell targeting

Publications (1)

Publication Number Publication Date
BRPI1013177A2 true BRPI1013177A2 (pt) 2016-04-12

Family

ID=42752167

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013177A BRPI1013177A2 (pt) 2009-05-28 2010-05-26 construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca

Country Status (7)

Country Link
US (1) US20120253017A1 (pt)
EP (1) EP2435067A2 (pt)
JP (1) JP2012528117A (pt)
CN (1) CN102481340A (pt)
BR (1) BRPI1013177A2 (pt)
CA (1) CA2763446A1 (pt)
WO (1) WO2010136508A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP2843051B1 (en) * 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
US20150361150A1 (en) * 2013-02-04 2015-12-17 Roger Williams Medical Center Methods and compositions for treating gastrointestinal stromal tumor (gist)
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
CA2950381C (en) * 2014-07-29 2021-02-23 Cellectis Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
CN105567719A (zh) * 2016-01-06 2016-05-11 北京嘉万生物技术有限公司 cTnⅠ主要表位区的重组表达及其抗体的制备方法
CN107326065B (zh) * 2016-04-29 2022-07-29 博尔诚（北京）科技有限公司 一种基因标识物的筛选方法及其应用
SG11201811290VA (en) * 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
TW201840584A (zh) * 2017-03-20 2018-11-16 美商歐樂根公司 針對vegf之僅含重鏈之抗體
KR20200040407A (ko) * 2018-10-10 2020-04-20 주식회사 노벨티노빌리티 신규 항-c-KIT 항체
KR20210094610A (ko) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003241313A1 (en) * 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US20110008345A1 (en) * 2007-11-30 2011-01-13 Claire Ashman Antigen-binding constructs

Also Published As

Publication number Publication date
WO2010136508A3 (en) 2011-02-24
US20120253017A1 (en) 2012-10-04
EP2435067A2 (en) 2012-04-04
CN102481340A (zh) 2012-05-30
WO2010136508A2 (en) 2010-12-02
JP2012528117A (ja) 2012-11-12
CA2763446A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
BRPI1013177A2 (pt) construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
IL274871A (en) Proteins that bind to human 23–IL antigen
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
BRPI1008145A2 (pt) proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
HK1174645A1 (en) Bispecific, tetravalent antigen binding proteins
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
PT2376537T (pt) Anticorpos humanos contra fator tecidual humano
DK2776466T3 (da) Albuminbindende antistoffer og bindingsfragmenter deraf
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BRPI0822756A2 (pt) sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca.
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
BRPI1013688A2 (pt) proteínas de ligação de il-17.
BRPI1009004A2 (pt) método para integrar diagnóstico e tratamento para tecidos internos, e, sistema para integrar diagnóstico e tratamento para tecidos internos
BR112013013584A2 (pt) endoscópio, e, método
BRPI0821168A2 (pt) anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
BRPI0918842A2 (pt) método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0924398A2 (pt) perexilina, metodo de tratamento de hfnef e programa de tratamento para tratar hfnef

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2367 DE 17-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.